From: Right ventricle involvement in patients with breast cancer treated with chemotherapy
T0 | P value T0 – T1 | T1 | P value T1 – T2 | T2 | P value T2 – T3 | T3 | |
---|---|---|---|---|---|---|---|
LVEDD (mm) | 32.3 (3.1) | 0.5 | 32.2 (2.6) | 0.13 | 32.1 (2.7) | 0.5 | 34.4 (8.7) |
LV-EDV (ml) | 78.7 (11.7) | 0.2 | 81.9 (10.3) | 0.1 | 79.1 (11.5) | 0.3 | 77.8 (11.6) |
LV-EF (%) | 62.2 (3.5) | 0.005 | 60.8 (3.6) | 0.0004 | 59.2 (4.9) | 0.2 | 58.4 (5.4) |
LV-GLS (%) | -20.5 (1.7) | <0.0001 | -18.9 (2.1) | 0.0012 | -17.7 (2.2) | 0.15 | -18.4 (2) |
RV-GLS (%) | -22.2 (2.5) | <0.0001 | -20.6 (2.5) | 0.0014 | -19.6 (2.7) | 0.14 | -21 (4.1) |
RV-FWLS (%) | -26.5 (3.8) | <0.0001 | -25.1 (3.8) | 0.0001 | -23.2 (3.9) | 0.3 | -24,6 (3.6) |
LV-3DEF (%) | 63.4 (3.8) | 0.008 | 61.9 (3.4) | 0.01 | 59.9 (4.7) | 0.07 | 57.4 (6.2) |
RV-3DEF (%) | 59.3 (4.6) | <0.0001 | 55.1 (4.1) | 0.41 | 54.1 (4.6) | 0.2 | 52.8 (6.1) |
TAPSE (mm) | 22.4 (2.8) | 0.3 | 22.2 (3.5) | 0.02 | 21.7 (2.4) | 0.09 | 22.3 (2.7) |
RV-S’ (cm/sec) | 13.5 (2) | 0.2 | 14.3 (2.4) | 0.02 | 13.3 (2) | 0.2 | 11.6 (7.4) |
FAC (%) | 49.9 (7.7) | 0.3 | 50.9 (4.8) | 0.9 | 50.7 (6.4) | 0.001 | 45.7 (4.7) |